The list of Dr Alvord's contributions to the field is impressive, and he had the ability to identify relevant research questions. In fact, many of the topics that caught his intellectual curiosity are again the focus of research for a new generation of investigators. In 1948, he published an article on the distribution of central nervous system autoantigen in EAE in the guinea pig. For the next 30 years, he mapped dominant determinants of myelin antigens in several species. He and his colleagues also identified the potential of myelin as a treatment of central nervous system autoimmune disease, an observation that was tested decades later in clinical studies. Together with other investigators from the Pacific Northwest (Don Paty, MD, included), Dr Alvord detected paraclinical disease activity in animals with EAE by magnetic resonance imaging in 1985. While he was one of the first to express caution regarding the limitations associated with the EAE model when studying multiple sclerosis, he was also one of the first to test antibodies against monospecific targets as therapy. In 1987, Dr Alvord and colleagues recognized the importance of age of infections in childhood in determining the risk of multiple sclerosis. In the same year, he studied the role of B cells in EAE, a cell type that had largely been ignored in this context.